Introduction
Heart failure (HF) is a manifestation of various end-state of heart diseases [
1,
2].The prevalence of HF, a serious public health problem, is increasing every year. The mortality rate of HF is high and seriously affects the quality of life of patients [
3]. As with many chronic diseases, up to 50% of patients with HF have some form of malnutrition in combination [
4]. Patients with HF suffer from inadequate intake due to liver congestion, intestinal edema, and impaired absorption, but at the same time cardiac metabolism and energy demands increase. This results in an imbalance between energy intake and expenditure [
5]. Malnutrition increases the length of hospital stay as well as the risk of rehospitalization and death in patients with cardiovascular disease and is considered to be an important influencing factor in poor patient prognosis [
6‐
8]. Appropriate nutritional interventions can reduce cardiovascular disease risk and improve clinical outcomes in patients with HF [
9]. In recent years, nutritional status has attracted attention as a modifiable risk factor for patients with HF [
10‐
13]. Routine nutritional screening is recommended for most patients with chronic and acute illnesses and for hospitalized patients to identify those at risk of malnutrition. Current guidelines for the management of HF also recommend the assessment of nutritional status in patients with chronic HF [
14,
15]. However, to a large extent, nutrition awareness and intervention by clinicians are inadequate. To date, there is no standardized method to determine the nutritional risk of HF patients. The prognostic nutritional index (PNI) is calculated from serum albumin and lymphocyte counts and can be used to detect cardiometabolic disorders in patients with HF, allowing for early detection of malabsorption and inflammatory disease. At present, PNI has been widely used as a method to assess nutritional status. Previous studies have shown that PNI is independently associated with adverse clinical outcomes in patients with acute HF with different levels of ejection fraction [
16]. Subsequent studies have found that PNI can independently predict the prognosis of patients with severe decompensated acute HF [
17].
Malnutrition is widespread and takes many forms. Overproduction and underproduction are usually the two directions of malnutrition. The double burden of malnutrition is manifested by the interaction of undernutrition and overweight/obesity, two forms of malnutrition that share many common drivers and have adverse effects on human health [
18]. . Going further, the double burden concept of malnutrition has also been proposed to extend to the individual. Obesity is the most common component of the metabolic syndrome (MS), which implies that overnutrition contributes to the syndrome. Obesity is an established risk factor for cardiovascular disease. Malnutrition may exacerbate the cardiac effects associated with chronic morbid obesity, and studies have shown that malnourished obese individuals have maladaptive cardiac remodeling and the worst cardiac outcomes [
19]. Most patients with MS present with obesity, which implies that overnutrition contributes to the syndrome [
20]. MS refers to a range of metabolism-related disorders, including glucose intolerance, insulin resistance, obesity, dyslipidemia, and type 2 diabetes [
21‐
23]. As a health problem in modern society, MS is associated with a huge social, personal, and economic burden in both developing and developed countries. Currently, it is calculated that MS affects approximately 25% of the global population [
24,
25].
To our knowledge, there are no relevant studies focusing on the impact of MS in malnourished HF patients. Many relevant studies have highlighted the importance of nutritional assessment in clinical practice, especially for the health management of end-stage patients with cardiac dysfunction [
9,
26]. Importantly, malnutrition not only refers to wasting/under-nutrition but also overweight/obesity [
18]. The prognosis of obese critically ill patients with malnutrition is worse compared to those without malnutrition [
27]. The aim of this study was to assess the impact of MS on the prognosis of malnourished HF patients.
Discussion
In our study, PNI was selected to assess the nutritional status of patients with HF, and low PNI levels were taken as evidence of malnutrition. Follow-up of malnourished HF patients showed that patients with MS had a worse prognosis. The survival probability of patients with MS is significantly lower than that of patients without MS. In malnourished HF patients, MS was independently associated with cardiovascular death and all-cause death.
Malnutrition is very common in patients with HF. Malnutrition occurs in patients with HF through a number of mechanisms due to intestinal edema and impaired intestinal barrier function, increased energy expenditure and decreased anabolism, and chronic inflammatory states [
5,
33,
34]. Patients with advanced chronic HF often develop cardiac cachexia, which manifests as muscle wasting and weight loss. Although malnutrition is associated with adverse outcomes in patients with cardiovascular disease, the nutritional status of patients with HF is often overlooked [
35,
36]. HF can lead to malnutrition, which, in turn, can lead to increased inflammation, neurohormonal activation, and fluid retention, further affecting HF and forming a vicious cycle [
37]. Nutritional assessment is important to clarify the nutritional status of patients and provides a useful predictor of disease risk. nutritional status is thought to influence the prognosis of patients with chronic HF, clarifying the nutritional status of patients for appropriate nutritional interventions can slow the progression of disease and improve the prognosis of patients with HF.
Nutritional screening tools may be affected by recall bias and response rates, and nutritional assessments based on objective biochemical indicators may be more accurate [
38‐
40], such as geriatric nutritional risk index (GNRI) [
41], nutritional risk index (NRI) [
42] and controlling nutritional status (CONUT) [
43]. For hospitalized patients with HF, GNRI and NRI may not be appropriate because increased volume load affects body weight. On the other hand, some HF patients receive statin therapy, which reduces their total cholesterol levels while also possibly affecting the accuracy of the score. Compared to other indicators such as this, PNI, combined with serum albumin level and lymphocyte count, may be a useful screening tool to identify patients at risk of malnutrition. Numerous studies have shown that albumin is a strong predictor of HF prognosis and a valuable tool for assessing nutritional status [
44]. However, serum albumin has a long half-life and is also susceptible to nonnutritional factors, such as the patient’s hydration status, infection, abnormal liver function, and nephrotic syndrome. Albumin alone may not provide a complete assessment of a patient’s nutritional status. Lymphocyte count is another determinant of the PNI score. Studies have shown that lymphocyte count is a strong predictor of death in patients with moderate to severe HF [
45]. Malnutrition can predispose patients to recurrent infections and cause chronic inflammation. Malnutrition is often associated with an impaired immune response leading to a decrease in lymphocytes [
46]. Studies have shown that malnutrition can induce apoptosis in peripheral blood lymphocytes [
47].
Undernutrition and overweight have historically been recognized as distinct challenges affecting different populations with different risk factors. Malnutrition encompasses many different manifestations of nutritional deficiencies, including undernutrition and obesity. These two forms of malnutrition are increasingly co-occurring in communities, households and even individuals [
48]. Similar to malnutrition, overnutrition may also result from an imbalance between nutritional intake and requirements. Both may disrupt metabolism. Obesity serves as an important aspect of malnutrition. Many studies have shown that obesity, especially excess abdominal fat, is associated with poor health. Delayed nutritional support and increased risk of malnutrition in obese patients may be due to the fact that the nutritional status of such patients is less visible to patients and caregivers. Obesity promotes inflammation, negatively affecting skeletal muscle and metabolic function. The burden of disease caused by obesity and related non-communicable diseases can be a serious public health challenge. With the increase in obesity, the prevalence of MS is also increasing dramatically. The MS is a group of metabolic disorders that includes obesity and is often thought to be the result of excess accumulation of lipids in organs or tissues due to excess nutrients and decreased energy expenditure [
49]. This, in turn, disrupts metabolic processes and makes patients vulnerable to metabolic risk factors [
20]. Epidemiological evidence defines MS as a highly prevalent worldwide disease [
50,
51]. This evidence is further supported by the global increase in overweight and obese populations and their impact on health care systems, economies, and quality of life [
52,
53]. In our study, compared with the non-MS group, BMI, SBP, DBP, FPG, TG, and BNP were significantly increased and HCL-C was significantly decreased in malnourished HF patients with MS. At the same time, patients in the MS group had a significantly lower survival rate, and MS was independently associated with the occurrence of adverse events in malnourished patients with HF. Previous studies have shown that the risk of cardiovascular disease increases with increasing components of MS [
54]. Similar findings were observed in malnourished patients. In conclusion, the results of our study suggest that malnutrition overlaps with risk factors for metabolic diseases, leading to an increased risk of poor prognosis in patients with HF, and the burdens of overnutrition and undernutrition need to be considered together rather than studied separately.
There are some limitations regarding our study that must be acknowledged. First, it was a single-center cohort study. Although we attempted to adjust for confounders, we cannot completely rule out the risk of bias and residual confounding. Considering the varying degrees of fluid overload in patients with HF, although most patients were treated with diuretic medications, the therapeutic effect was unclear and may have influenced the diagnosis of MS. Also, some patients were followed up by telephone contact with family members, so the results were not completely reliable. Our results do not include other relevant end-point events, and future studies should be designed to further characterize the spectrum of cardiovascular outcomes. The concept of malnutrition in obesity/MS still requires further research and consensus initiatives to better clarify its definition, diagnostic criteria, and treatment options.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.